NICE guidelines on anti-tumor necrosis factor therapy for RA.
Scott
David L
DL
Department of Rheumatology, King's College Hospital, London, UK. david.l.scott@kcl.ac.uk
Steer
Sophia
S
D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006801:Humans; D007596:Joints / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D006113:United Kingdom
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha